Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine candidate is protective in macaques

Cyril, Le Nouën, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Chrsitine E, Nelson, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Xueqiao, Liu, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Hong-Su, Park, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Yumiko, Matsuoka, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Cindy, Luongo, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Celia, Santos, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Lijuan, Yang, National Institute of Allergy and Infectious Diseases, NIH, BethesdaNational Institute of Allergy and Infectious Diseases, NIH, Bethesda; Ricard, Herbert, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Ashley, Castens, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Ian, Moore, Emory University; Temeri, Wilder-Kofie, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Rashida, Moore, Emory University; April, Walker, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Peng, Zhang, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Paolo, Lusso, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Reed F, Johnson, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Nicole L, Garza, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Laura E, Via, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Shirin, Munir, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Daniel, Barber, National Institute of Allergy and Infectious Diseases, NIH, Bethesda; Ursula J, Buchholz, National Institute of Allergy and Infectious Diseases, NIH, Bethesda

Persistent URL

https://open.library.emory.edu/purl/600ns1rp82-emory

Last modified

09/09/2025

Type of Material

Article

Authors

Cyril Le Nouën, National Institute of Allergy and Infectious Diseases, NIH, Bethesda

Chrsitine E Nelson, National Institute of Allergy and Infectious Diseases, NIH, Bethesda

Xueqiao Liu, National Institute of Allergy and Infectious Diseases, NIH, Bethesda

Hong-Su Park, National Institute of Allergy and Infectious Diseases, NIH, Bethesda

Yumiko Matsuoka, National Institute of Allergy and Infectious Diseases, NIH, Bethesda

Cindy Luongo, National Institute of Allergy and Infectious Diseases, NIH, BethesdaCelia Santos, National Institute of Allergy and Infectious Diseases, NIH, BethesdaLijuan Yang, National Institute of Allergy and Infectious Diseases, NIH, BethesdaNational Institute of Allergy and Infectious Diseases, NIH, BethesdaRicard Herbert, National Institute of Allergy and Infectious Diseases, NIH, BethesdaAshley Castens, National Institute of Allergy and Infectious Diseases, NIH, BethesdaIan Moore, Emory UniversityTemeri Wilder-Kofie, National Institute of Allergy and Infectious Diseases, NIH, BethesdaRashida Moore, Emory UniversityApril Walker, National Institute of Allergy and Infectious Diseases, NIH, BethesdaPeng Zhang, National Institute of Allergy and Infectious Diseases, NIH, BethesdaPaolo Lusso, National Institute of Allergy and Infectious Diseases, NIH, BethesdaReed F Johnson, National Institute of Allergy and Infectious Diseases, NIH, BethesdaNicole L Garza, National Institute of Allergy and Infectious Diseases, NIH, BethesdaLaura E Via, National Institute of Allergy and Infectious Diseases, NIH, BethesdaShirin Munir, National Institute of Allergy and Infectious Diseases, NIH, BethesdaDaniel Barber, National Institute of Allergy and Infectious Diseases, NIH, BethesdaUrsula J Buchholz, National Institute of Allergy and Infectious Diseases, NIH, Bethesda

Language

English

Date

2022-05-23

Publisher

NIH

Publication Version

Preprint (Prior to Peer Review)

Copyright Statement

The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105.

License

Creative Commons Universal : Public Domain Dedication

Final Published Version (URL)

http://dx.doi.org/10.1101/2022.05.21.492923

Title of Journal or Parent Work

bioRxiv

Supplemental Material (URL)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164439/bin/media-1.pdf

Abstract

Pediatric SARS-CoV-2 vaccines are needed that elicit immunity directly in the airways, as well as systemically. Building on pediatric parainfluenza virus vaccines in clinical development, we generated a live-attenuated parainfluenza virus-vectored vaccine candidate expressing SARS-CoV-2 prefusion-stabilized spike (S) protein (B/HPIV3/S-6P) and evaluated its immunogenicity and protective efficacy in rhesus macaques. A single intranasal/intratracheal dose of B/HPIV3/S-6P induced strong S-specific airway mucosal IgA and IgG responses. High levels of S-specific antibodies were also induced in serum, which efficiently neutralized SARS-CoV-2 variants of concern. Furthermore, B/HPIV3/S-6P induced robust systemic and pulmonary S-specific CD4+ and CD8+ T-cell responses, including tissue-resident memory cells in lungs. Following challenge, SARS-CoV-2 replication was undetectable in airways and lung tissues of immunized macaques. B/HPIV3/S-6P will be evaluated clinically as pediatric intranasal SARS-CoV-2/parainfluenza virus type 3 vaccine.

Author Notes